← United States · Coverage record
US · SEC FORM 4
Skye Bioscience, Inc.
SKYE · Nasdaq · CIK 0001516551 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
31 Form 4 transaction lines observed in the same window
30 sales · 1 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-03-13 · 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 147,954
- Previous report
- 117,086
- Avg daily volume
- 85,208
- Days to cover
- 1.7
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2024-03-13 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | Purchase (P) | Common Stock | 450,000 | USD 10.00 | USD 4,500,000 | SEC filing ↗ |
| 2024-01-31 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | Purchase (P) | Common Stock | 5,206,074 | USD 2.31 | USD 12,026,031 | SEC filing ↗ |
| 2023-08-29 | DHILLON PUNIT | Purchase (P) | Common Stock | 881,000 | USD 0.02 | USD 17,620 | SEC filing ↗ |
| 2023-08-29 | DHILLON PUNIT | Purchase (P) | Common Stock | 881,000 | USD 0.02 | USD 17,620 | SEC filing ↗ |
| 2020-08-07 | HEPPELL JAMES L | Purchase (P) | Common Stock | 500,000 | USD 50,000.00 | USD 25,000,000,000 | SEC filing ↗ |
| 2020-08-07 | DHILLON PUNIT | Purchase (P) | Common Stock | 1,000,000 | USD 100,000.00 | USD 100,000,000,000 | SEC filing ↗ |
Form 4 evidence
31 transaction lines in the latest 365-day window; 103 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Schwab Andrew J. | Sale (S) | Common Stock | 119,379 | USD 1.61 | USD 192,200 | SEC filing ↗ |
| 2026-09-23 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | Sale (S) | Common Stock | 119,379 | USD 1.61 | USD 192,200 | SEC filing ↗ |
| 2026-09-22 | Schwab Andrew J. | Sale (S) | Common Stock | 28,700 | USD 1.65 | USD 47,355 | SEC filing ↗ |
Show recent Form 4 evidence (13 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Schwab Andrew J. | Sale (S) | Common Stock | 119,379 | USD 1.61 | USD 192,200 | SEC filing ↗ |
| 2026-09-23 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | Sale (S) | Common Stock | 119,379 | USD 1.61 | USD 192,200 | SEC filing ↗ |
| 2026-09-22 | Schwab Andrew J. | Sale (S) | Common Stock | 28,700 | USD 1.65 | USD 47,355 | SEC filing ↗ |
| 2026-09-22 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | Sale (S) | Common Stock | 28,700 | USD 1.65 | USD 47,355 | SEC filing ↗ |
| 2026-09-16 | Schwab Andrew J. | Sale (S) | Common Stock | 33,892 | USD 1.91 | USD 64,734 | SEC filing ↗ |
| 2026-09-16 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | Sale (S) | Common Stock | 33,892 | USD 1.91 | USD 64,734 | SEC filing ↗ |
| 2026-08-20 | Schwab Andrew J. | Sale (S) | Common Stock | 7,700 | USD 0.32 | USD 2,464 | SEC filing ↗ |
| 2026-08-20 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | Sale (S) | Common Stock | 7,700 | USD 0.32 | USD 2,464 | SEC filing ↗ |
| 2026-08-19 | Schwab Andrew J. | Sale (S) | Common Stock | 68,140 | USD 0.35 | USD 23,849 | SEC filing ↗ |
| 2026-08-19 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | Sale (S) | Common Stock | 68,140 | USD 0.35 | USD 23,849 | SEC filing ↗ |
| 2026-08-18 | Schwab Andrew J. | Sale (S) | Common Stock | 300,000 | USD 0.38 | USD 114,000 | SEC filing ↗ |
| 2026-08-18 | 5AM CO-INVESTORS II LP; 5AM Partners II, LLC; 5AM Partners VII, LLC; 5AM Ventures II LP; 5AM Ventures VII, L.P.; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M | Sale (S) | Common Stock | 300,000 | USD 0.38 | USD 114,000 | SEC filing ↗ |
| 2026-08-07 | DHILLON PUNIT | Award / grant (A) | Common Stock | 1,090,000 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | SKYE |
| CIK | 0001516551 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 103 transaction lines from 2020-08-07 to 2026-09-23 6 P purchase lines · 63 S sale lines · 34 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.